Patrick Musole Bugeme
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Patrick Musole Bugeme has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Jackie Knee
London School of Hygiene and Tropical Medicine
8 shared publications - Andrew S. Azman
Johns Hopkins University
7 shared publications - Daniel Mukadi-Bamuleka
Service de Microbiologie, Département de Biologie Médicale, Cliniques Universitaires de Kinshasa, Université de Kinshasa, Kinshasa, Democratic Republic of the Congo
7 shared publications - Espoir Bwenge Malembaka
Center for Tropical Diseases and Global Health, Université Catholique de Bukavu, Bukavu, Democratic Republic of the Congo
7 shared publications Justin Bengehya
Division Provinciale de la Santé Publique du Sud-Kivu, Bukavu, Democratic Republic of the Congo (J.B.)
6 shared publications- Justin Lessler
University of North Carolina at Chapel Hill
6 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Public Library of Science (PLoS) in PLOS Water
- Vol. 5 (10) , e0000646
Pragmatic water and health research in a complex emergency: Learnings and way forward
Climate change is straining water and sanitation services (WSS), leading to disruptions that threaten public health. In low-income and fragile contexts, there is an urgent need to increase investments in WSS, as well as to enhance efficiency in the utilisation of available financial resources. Operational research can help optimise future investments in WSS. In this perspective, we share our experience carrying out research embedded within a large-scale water supply infrastructure improvement programme in an urban, cholera-endemic area in South Kivu (Democratic Republic of the Congo). Through the lens of this concrete example, we highlight the need for rigorous research on higher quality drinking water services in low-income and fragile countries, discuss how multi-stakeholder research partnerships and pragmatic methods can contribute to the generation of rigorous evidence where it is most needed, and illustrate the role of research in strengthening capacities for both science and practice.
- 8 October 2026
- Published by Public Library of Science (PLoS) in PLOS Water
- Vol. 5 (10) , e0000646
Open AccessPragmatic water and health research in a complex emergency: Learnings and way forward
Climate change is straining water and sanitation services (WSS), leading to disruptions that threaten public health. In low-income and fragile contexts, there is an urgent need to increase investments in WSS, as well as to enhance efficiency in the utilisation of available financial resources. Operational research can help optimise future investments in WSS. In this perspective, we share our experience carrying out research embedded within a large-scale water supply infrastructure improvement programme in an urban, cholera-endemic area in South Kivu (Democratic Republic of the Congo). Through the lens of this concrete example, we highlight the need for rigorous research on higher quality drinking water services in low-income and fragile countries, discuss how multi-stakeholder research partnerships and pragmatic methods can contribute to the generation of rigorous evidence where it is most needed, and illustrate the role of research in strengthening capacities for both science and practice.
- Open Access
Impact of mass oral cholera vaccination in an endemic area of the Democratic Republic of the Congo: a surveillance-based counterfactual modeling analysis
Background: Oral cholera vaccines (OCVs) are a key component of cholera control recommended in cholera-endemic areas. Yet evidence of their population-level impact is limited, especially in Africa where most cholera deaths occur. Here, we estimate the impact of mass administration of OCVs in the cholera-endemic city of Uvira, Democratic Republic of the Congo. Methods: We conducted enhanced cholera surveillance at the two official cholera treatment facilities in Uvira between Jan 2017 and Dec 2023, centered around a mass vaccination campaign that achieved 66% coverage with at least one dose of Euvichol Plus vaccine in 2020. We combined systematic rapid diagnostic case testing with repeated, representative population surveys capturing healthcare-seeking behavior, vaccination, population mobility, and antibody profiles to estimate seroincidence. We developed a Bayesian framework that integrates these data into an ensemble of mechanistic cholera transmission models that account for time-varying transmissibility, realistic immunity dynamics and loss of vaccination coverage to population turnover. OCV impact was assessed through ensemble counterfactual modeling of alternative vaccination scenarios. Findings: We estimate that the 2020 mass vaccination averted 56% (95% Credible Interval: 34-81) of infections and deaths over the subsequent three years. This corresponds to 2,350 (median, 95% CrI: 890-8,960) averted facility-attended cases, and 44 (median, 95% CrI: 16-150) averted facility and community deaths. Vaccination of all of Uvira’s eligible population would have averted 64% (median, 95% CrI: 43-87) of cases and deaths, with a negative but limited influence of vaccine coverage loss because of population turnover (71% median, 95% CrI: 52-90 at half the population turnover). Interpretation: Although mass vaccination averted a significant fraction of cholera cases that would have otherwise occurred in this endemic setting, imperfect coverage, population turnover, and high transmission rates contributed in offsetting the larger potential benefits of OCV. Successful cholera control in Uvira hinges on multisectorial approaches including provision of safe water and sanitation. Setting and communicating realistic expectations for mass vaccination programs in highly endemic areas is critical for maintaining confidence in the current generation of OCVs. Funding: Gavi (M&E 9166 09 20 A16) and the Wellcome Trust (221688/Z/20/Z). Research in Context: Evidence before this study: We searched PubMed for studies published between January 1, 2000 and June 2026 using the terms (“oral cholera vaccine” OR “OCV”) AND (“vaccine effectiveness” OR “vaccine impact” OR “indirect protection” OR “herd immunity” OR “population-level protection”). We also reviewed World Health Organisation (WHO) position papers and reports from the Global Task Force on Cholera Control (GTFCC). Inactivated oral cholera vaccines provide strong direct protection against symptomatic cholera, with randomized controlled trials and observational studies reporting effectiveness estimates typically exceeding 50% in the first three years after vaccination. In a previous study we showed that one-dose vaccine effectiveness was 52% 12-17 months after vaccination in Uvira, DRC. However, evidence on the population-level impact of preventive mass vaccination campaigns, which encompasses both direct and indirect protection, is thin. The only published estimates from clinical trials, both conducted in South Asia, reported overall protection of 37% over a 2-year period in Dhaka, Bangladesh and 75% over a 3-year period in Kolkata, India. No rigorous real-world estimates of mass OCV impact have been published from sub-Saharan Africa, where the vast majority of global cholera deaths occur. A major obstacle behind this gap is the lack of high-quality pre- and post-vaccination surveillance to support robust estimation of impact. The WHO and GTFCC have identified this evidence gap as a major research priority. Added value of this study: To our knowledge, this is the first study to provide a rigorous, data-driven estimate of the population-level impact of a preventive mass OCV campaign in a cholera-endemic African setting. Drawing on 7 years of enhanced clinical surveillance, three population-representative household surveys measuring vaccine coverage, population mobility and health-care seeking behaviors, a serological survey, and a novel ensemble of compartmental transmission models, we estimated that the 2020 campaign in Uvira, DRC — which achieved approximately 66% coverage of at least one dose of Euvichol Plus vaccine — averted 56% (95% CrI: 34-81) of cholera cases and deaths over the subsequent three years. This corresponds to 2,350 (median, 95% CrI: 890-8,960) averted cases that would have sought care at official cholera treatment facilities, and 44 (median, 95% CrI: 16-150) averted deaths. Our transmission modeling framework also yielded new insights into cholera natural history in this endemic setting: symptomatic infection conferred strong and durable immunity (mean duration 6 years), while immunity following asymptomatic infection was substantially weaker. We further quantify how vaccination coverage and population turnover jointly determine vaccination program impact, providing a practical framework for informing future campaign design. Implications of all the available evidence: Taken together with prior evidence from South Asia, our findings indicate that preventive mass OCV campaigns can avert a substantial fraction of cholera cases and deaths in highly endemic settings across different epidemiological contexts. Nonetheless, the resurgence of cholera a year after the vaccination campaign underscores that OCV campaigns alone are insufficient for sustained cholera control in similar settings due to high transmission rates and high population...
Open AccessImpact of mass oral cholera vaccination in an endemic area of the Democratic Republic of the Congo: a surveillance-based counterfactual modeling analysis
Background: Oral cholera vaccines (OCVs) are a key component of cholera control recommended in cholera-endemic areas. Yet evidence of their population-level impact is limited, especially in Africa where most cholera deaths occur. Here, we estimate the impact of mass administration of OCVs in the cholera-endemic city of Uvira, Democratic Republic of the Congo. Methods: We conducted enhanced cholera surveillance at the two official cholera treatment facilities in Uvira between Jan 2017 and Dec 2023, centered around a mass vaccination campaign that achieved 66% coverage with at least one dose of Euvichol Plus vaccine in 2020. We combined systematic rapid diagnostic case testing with repeated, representative population surveys capturing healthcare-seeking behavior, vaccination, population mobility, and antibody profiles to estimate seroincidence. We developed a Bayesian framework that integrates these data into an ensemble of mechanistic cholera transmission models that account for time-varying transmissibility, realistic immunity dynamics and loss of vaccination coverage to population turnover. OCV impact was assessed through ensemble counterfactual modeling of alternative vaccination scenarios. Findings: We estimate that the 2020 mass vaccination averted 56% (95% Credible Interval: 34-81) of infections and deaths over the subsequent three years. This corresponds to 2,350 (median, 95% CrI: 890-8,960) averted facility-attended cases, and 44 (median, 95% CrI: 16-150) averted facility and community deaths. Vaccination of all of Uvira’s eligible population would have averted 64% (median, 95% CrI: 43-87) of cases and deaths, with a negative but limited influence of vaccine coverage loss because of population turnover (71% median, 95% CrI: 52-90 at half the population turnover). Interpretation: Although mass vaccination averted a significant fraction of cholera cases that would have otherwise occurred in this endemic setting, imperfect coverage, population turnover, and high transmission rates contributed in offsetting the larger potential benefits of OCV. Successful cholera control in Uvira hinges on multisectorial approaches including provision of safe water and sanitation. Setting and communicating realistic expectations for mass vaccination programs in highly endemic areas is critical for maintaining confidence in the current generation of OCVs. Funding: Gavi (M&E 9166 09 20 A16) and the Wellcome Trust (221688/Z/20/Z). Research in Context: Evidence before this study: We searched PubMed for studies published between January 1, 2000 and June 2026 using the terms (“oral cholera vaccine” OR “OCV”) AND (“vaccine effectiveness” OR “vaccine impact” OR “indirect protection” OR “herd immunity” OR “population-level protection”). We also reviewed World Health Organisation (WHO) position papers and reports from the Global Task Force on Cholera Control (GTFCC). Inactivated oral cholera vaccines provide strong direct protection against symptomatic cholera, with randomized controlled trials and observational studies reporting effectiveness estimates typically exceeding 50% in the first three years after vaccination. In a previous study we showed that one-dose vaccine effectiveness was 52% 12-17 months after vaccination in Uvira, DRC. However, evidence on the population-level impact of preventive mass vaccination campaigns, which encompasses both direct and indirect protection, is thin. The only published estimates from clinical trials, both conducted in South Asia, reported overall protection of 37% over a 2-year period in Dhaka, Bangladesh and 75% over a 3-year period in Kolkata, India. No rigorous real-world estimates of mass OCV impact have been published from sub-Saharan Africa, where the vast majority of global cholera deaths occur. A major obstacle behind this gap is the lack of high-quality pre- and post-vaccination surveillance to support robust estimation of impact. The WHO and GTFCC have identified this evidence gap as a major research priority. Added value of this study: To our knowledge, this is the first study to provide a rigorous, data-driven estimate of the population-level impact of a preventive mass OCV campaign in a cholera-endemic African setting. Drawing on 7 years of enhanced clinical surveillance, three population-representative household surveys measuring vaccine coverage, population mobility and health-care seeking behaviors, a serological survey, and a novel ensemble of compartmental transmission models, we estimated that the 2020 campaign in Uvira, DRC — which achieved approximately 66% coverage of at least one dose of Euvichol Plus vaccine — averted 56% (95% CrI: 34-81) of cholera cases and deaths over the subsequent three years. This corresponds to 2,350 (median, 95% CrI: 890-8,960) averted cases that would have sought care at official cholera treatment facilities, and 44 (median, 95% CrI: 16-150) averted deaths. Our transmission modeling framework also yielded new insights into cholera natural history in this endemic setting: symptomatic infection conferred strong and durable immunity (mean duration 6 years), while immunity following asymptomatic infection was substantially weaker. We further quantify how vaccination coverage and population turnover jointly determine vaccination program impact, providing a practical framework for informing future campaign design. Implications of all the available evidence: Taken together with prior evidence from South Asia, our findings indicate that preventive mass OCV campaigns can avert a substantial fraction of cholera cases and deaths in highly endemic settings across different epidemiological contexts. Nonetheless, the resurgence of cholera a year after the vaccination campaign underscores that OCV campaigns alone are insufficient for sustained cholera control in similar settings due to high transmission rates and high population...
- 1 February 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (2) , 207-215
The Incubation Periods of Mpox Virus Clade Ib
Mpox virus (MPXV) clade Ib, first detected in the Democratic Republic of the Congo (DRC) in September 2023, spread internationally within months, prompting an emergency declaration from the World Health Organization. Data on its incubation period, which both shapes outbreak dynamics and informs epidemic response strategies, remain limited. To estimate the incubation periods of mpox clade Ib, examining evidence for differences by route of exposure and demographic factors. Bayesian analysis of clinical surveillance data collected between June and October 2024. South Kivu, DRC, the epicenter of the current mpox clade Ib global outbreak. Clinically attended persons with confirmed mpox clade Ib infection. Demographic characteristics, exposure history, symptom onset, and transmission route. Among 37 polymerase chain reaction-confirmed cases with high viral load (cycle threshold values <34), the median incubation period from exposure to rash was 13.6 days (95% credible interval [CrI], 9.6 to 19.0 days). Five percent of cases are expected to develop a rash within 3.1 days (CrI, 1.3 to 5.5 days) and 95% within 32.3 days (CrI, 22.4 to 45.8 days). The incubation period seemed to differ by putative transmission route: Sexual transmission had a shorter median (10.3 days [CrI, 3.1 to 20.3 days]) than nonsexual transmission (13.5 days [CrI, 9.5 to 19.1 days]), although the CrIs overlapped. Surveillance data lacked detailed exposure histories and a lower bound for exposure periods, but models accounted for these uncertainties, yielding robust median estimates. Evidence from this study suggests that clade Ib may have a longer incubation period than other MPXV clades, and this may vary by transmission route. The shorter incubation for sexual transmission mirrors patterns seen in the predominantly sexually transmitted clade IIb outbreak, highlighting the potential role of exposure route in disease progression. These findings have implications for global recommendations on postexposure monitoring periods and prophylaxis. Gates Foundation and Geneva Centre for Emerging Viral Diseases.
- 1 February 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (2) , 207-215
The Incubation Periods of Mpox Virus Clade Ib
Mpox virus (MPXV) clade Ib, first detected in the Democratic Republic of the Congo (DRC) in September 2023, spread internationally within months, prompting an emergency declaration from the World Health Organization. Data on its incubation period, which both shapes outbreak dynamics and informs epidemic response strategies, remain limited. To estimate the incubation periods of mpox clade Ib, examining evidence for differences by route of exposure and demographic factors. Bayesian analysis of clinical surveillance data collected between June and October 2024. South Kivu, DRC, the epicenter of the current mpox clade Ib global outbreak. Clinically attended persons with confirmed mpox clade Ib infection. Demographic characteristics, exposure history, symptom onset, and transmission route. Among 37 polymerase chain reaction-confirmed cases with high viral load (cycle threshold values <34), the median incubation period from exposure to rash was 13.6 days (95% credible interval [CrI], 9.6 to 19.0 days). Five percent of cases are expected to develop a rash within 3.1 days (CrI, 1.3 to 5.5 days) and 95% within 32.3 days (CrI, 22.4 to 45.8 days). The incubation period seemed to differ by putative transmission route: Sexual transmission had a shorter median (10.3 days [CrI, 3.1 to 20.3 days]) than nonsexual transmission (13.5 days [CrI, 9.5 to 19.1 days]), although the CrIs overlapped. Surveillance data lacked detailed exposure histories and a lower bound for exposure periods, but models accounted for these uncertainties, yielding robust median estimates. Evidence from this study suggests that clade Ib may have a longer incubation period than other MPXV clades, and this may vary by transmission route. The shorter incubation for sexual transmission mirrors patterns seen in the predominantly sexually transmitted clade IIb outbreak, highlighting the potential role of exposure route in disease progression. These findings have implications for global recommendations on postexposure monitoring periods and prophylaxis. Gates Foundation and Geneva Centre for Emerging Viral Diseases.
- Open Access
- 18 December 2025
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 30 (50)
Community transmission of mpox clade Ib not driven through sexual exposures, Uvira, eastern Democratic Republic of the Congo, June to October 2024
BACKGROUND: In September 2023, monkeypox virus (MPXV) clade Ib emerged in Kamituga, a mining zone in South Kivu, Democratic Republic of the Congo (DRC), primarily through sexual transmission. AIM: We aimed to investigate cases in a MPXV clade Ib outbreak in Uvira, eastern DRC. METHODS: From June to October 2024, we collected demographic, exposure and clinical data from suspected mpox cases at Uvira hospital and in households. The virus was identified by PCR. We investigated putative transmission patterns, disease severity and risk factors. RESULTS: We identified 973 suspected cases: 415 (42.7%) were tested with PCR and 322 (77.6%) were confirmed. The median age of suspected cases was 9 years (interquartile range (IQR): 3–20 years), with 620 (63.7%) aged < 15 and 344 (35.4%) < 5 years. Severe disease (≥ 100 lesions) was more common in cases aged < 15 years (25.6%; 142/554) than others (16.1%; 49/304; p < 0.001). Twenty-two (12.2%) of 181 cases aged < 5 years had acute malnutrition. Seven cases died; the overall case-fatality ratio was 0.7%, and in infants (aged < 1 year) it was 3.9% (5/127). Of 329 suspected cases tested for HIV, six (1.8%) were positive. Nineteen (14.5%) of 131 females aged 15–49 years were pregnant. Most reported exposures to suspected mpox cases occurred in households (67.9%; 298/439). Sexual (6.0%; 19/318) or healthcare-related occupational exposures (1.4%; 6/417) were less common. Animal exposures were few (5.0%; 39/776) and predominantly domestic (97.4%; 38/39). CONCLUSION: This child-centred outbreak, driven by non-sexual transmission, underscores the need for paediatric vaccines, nutritional support and household interventions. Adult-focused responses alone may be insufficient to control the outbreak.
- 18 December 2025
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 30 (50)
Open AccessCommunity transmission of mpox clade Ib not driven through sexual exposures, Uvira, eastern Democratic Republic of the Congo, June to October 2024
BACKGROUND: In September 2023, monkeypox virus (MPXV) clade Ib emerged in Kamituga, a mining zone in South Kivu, Democratic Republic of the Congo (DRC), primarily through sexual transmission. AIM: We aimed to investigate cases in a MPXV clade Ib outbreak in Uvira, eastern DRC. METHODS: From June to October 2024, we collected demographic, exposure and clinical data from suspected mpox cases at Uvira hospital and in households. The virus was identified by PCR. We investigated putative transmission patterns, disease severity and risk factors. RESULTS: We identified 973 suspected cases: 415 (42.7%) were tested with PCR and 322 (77.6%) were confirmed. The median age of suspected cases was 9 years (interquartile range (IQR): 3–20 years), with 620 (63.7%) aged < 15 and 344 (35.4%) < 5 years. Severe disease (≥ 100 lesions) was more common in cases aged < 15 years (25.6%; 142/554) than others (16.1%; 49/304; p < 0.001). Twenty-two (12.2%) of 181 cases aged < 5 years had acute malnutrition. Seven cases died; the overall case-fatality ratio was 0.7%, and in infants (aged < 1 year) it was 3.9% (5/127). Of 329 suspected cases tested for HIV, six (1.8%) were positive. Nineteen (14.5%) of 131 females aged 15–49 years were pregnant. Most reported exposures to suspected mpox cases occurred in households (67.9%; 298/439). Sexual (6.0%; 19/318) or healthcare-related occupational exposures (1.4%; 6/417) were less common. Animal exposures were few (5.0%; 39/776) and predominantly domestic (97.4%; 38/39). CONCLUSION: This child-centred outbreak, driven by non-sexual transmission, underscores the need for paediatric vaccines, nutritional support and household interventions. Adult-focused responses alone may be insufficient to control the outbreak.
- Open Access
Community transmission of Mpox clade Ib not driven through sexual exposures in Uvira, eastern Democratic Republic of Congo, June – October 2024
Introduction In September 2023, mpox clade Ib emerged in Kamituga, a mining zone in South Kivu, DR Congo, primarily through sexual transmission. This study investigates an mpox clade Ib outbreak in Uvira, an urban area 360 km from Kamituga, where the first case was reported in May 2024. Methods From June to October 2024, clinical and household data from suspected mpox cases were collected at Uvira hospital and household investigations. Mpox laboratory confirmation was performed via PCR. We analyzed demographic, exposure, and clinical data to characterize putative transmission patterns, severity, and risk factors. Results Among 973 suspected cases, 42.7% (415) had PCR results, with 77.6% (n=322) testing positive. The median age of suspected cases was 9 years (IQR: 3–20), with 63.7% under-15 (n=620) and 32.1% under-5 (n=312). Severe cases (≥100 lesions) were more frequent in children under 15 (25.6%, 142/554) than others (16.1%, 49/304; pConclusion This child-centered outbreak, driven by non-sexual transmission, underscores the need for pediatric vaccines, nutritional support, and household interventions. Adult-focused responses alone may be insufficient.
Open AccessCommunity transmission of Mpox clade Ib not driven through sexual exposures in Uvira, eastern Democratic Republic of Congo, June – October 2024
Introduction In September 2023, mpox clade Ib emerged in Kamituga, a mining zone in South Kivu, DR Congo, primarily through sexual transmission. This study investigates an mpox clade Ib outbreak in Uvira, an urban area 360 km from Kamituga, where the first case was reported in May 2024. Methods From June to October 2024, clinical and household data from suspected mpox cases were collected at Uvira hospital and household investigations. Mpox laboratory confirmation was performed via PCR. We analyzed demographic, exposure, and clinical data to characterize putative transmission patterns, severity, and risk factors. Results Among 973 suspected cases, 42.7% (415) had PCR results, with 77.6% (n=322) testing positive. The median age of suspected cases was 9 years (IQR: 3–20), with 63.7% under-15 (n=620) and 32.1% under-5 (n=312). Severe cases (≥100 lesions) were more frequent in children under 15 (25.6%, 142/554) than others (16.1%, 49/304; pConclusion This child-centered outbreak, driven by non-sexual transmission, underscores the need for pediatric vaccines, nutritional support, and household interventions. Adult-focused responses alone may be insufficient.
- Open Access
The incubation periods of Monkeypox virus clade Ib
Background Monkeypox virus (MPXV) clade Ib, first detected in Democratic Republic of the Congo (DRC) in September 2023, spread internationally within months, prompting a WHO emergency declaration. Data on how this clade differs from others, including the incubation period which both shapes outbreak dynamics and informs epidemic response strategies, remain limited. Methods We use clinical, laboratory and reported exposure data from suspected and qPCR-confirmed mpox cases in Uvira, DRC to estimate the incubation period for MPXV clade 1b. We developed a Bayesian model to estimate incubation periods of various symptom onset definitions (rash, fever, any symptom), demographic factors and putative transmission route (sexual vs. non-sexual). Results Among 92 PCR-confirmed cases, the median incubation period from exposure to rash was 18.6 days (95% CrI: 15.2-22.6). Five percent of cases are expected to develop a rash within 5.4 days (95% CrI; 3.4-7.6) and 95% within 37.6 days (95% CrI: 30.3-47.0). The incubation period differed by putative transmission route: sexual transmission had a shorter median (9.5 days, 95% CrI 3.7-16.4) than non-sexual transmission (18.9 days, 95% CrI: 15.3-23.0). Conclusions Incubation periods for clade Ib are longer than previous estimates for other MPXV clades, but vary strongly by sexual vs. non-sexual exposures, the former closely aligning with observations from the predominantly sexually transmitted clade IIa global outbreak. These findings highlight the significant differences by transmission route – likely reflecting differences in infectious viral dose and suggest the need to revise global post-exposure monitoring recommendations.
Open AccessThe incubation periods of Monkeypox virus clade Ib
Background Monkeypox virus (MPXV) clade Ib, first detected in Democratic Republic of the Congo (DRC) in September 2023, spread internationally within months, prompting a WHO emergency declaration. Data on how this clade differs from others, including the incubation period which both shapes outbreak dynamics and informs epidemic response strategies, remain limited. Methods We use clinical, laboratory and reported exposure data from suspected and qPCR-confirmed mpox cases in Uvira, DRC to estimate the incubation period for MPXV clade 1b. We developed a Bayesian model to estimate incubation periods of various symptom onset definitions (rash, fever, any symptom), demographic factors and putative transmission route (sexual vs. non-sexual). Results Among 92 PCR-confirmed cases, the median incubation period from exposure to rash was 18.6 days (95% CrI: 15.2-22.6). Five percent of cases are expected to develop a rash within 5.4 days (95% CrI; 3.4-7.6) and 95% within 37.6 days (95% CrI: 30.3-47.0). The incubation period differed by putative transmission route: sexual transmission had a shorter median (9.5 days, 95% CrI 3.7-16.4) than non-sexual transmission (18.9 days, 95% CrI: 15.3-23.0). Conclusions Incubation periods for clade Ib are longer than previous estimates for other MPXV clades, but vary strongly by sexual vs. non-sexual exposures, the former closely aligning with observations from the predominantly sexually transmitted clade IIa global outbreak. These findings highlight the significant differences by transmission route – likely reflecting differences in infectious viral dose and suggest the need to revise global post-exposure monitoring recommendations.
- Open Access
COVID-19 Vaccine Hesitancy and Associated Oral Cholera Vaccine Hesitancy in a Cholera-Endemic Country: A Community-Based Cross-Sectional Study in the Democratic Republic of Congo
COVID-19 vaccine hesitancy and its enablers shape community uptake of non-covid vaccines such as the oral cholera vaccine (OCV) in the post-COVID-19 era. This study assessed the impact of COVID-19 vaccine hesitancy and its drivers on OCV hesitancy in a cholera-endemic region of the Democratic Republic of Congo. We conducted a community-based survey in Bukavu. The survey included demographics, intention to take OCV and COVID-19 vaccines, reasons for COVID-19 hesitancy, and thoughts and feelings about COVID-19 vaccines. Poisson regression analyses were performed. Of the 1708 respondents, 84.66% and 77.57% were hesitant to OCV alone and to both OCV and COVID-19, respectively. Hesitancy to COVID-19 vaccines rose OCV hesitancy by 12% (crude prevalence ratio, [cPR] = 1.12, 95%CI [1.03–1.21]). Independent predictors of OCV hesitancy were living in a semi-urban area (adjusted prevalence ratio [aPR] = 1.10, 95%CI [1.03–1.12]), religious refusal of vaccines (aPR = 1.06, 95%CI [1.02–1.12]), concerns about vaccine safety (aPR = 1.05, 95%CI [1.01–1.11]) and adverse effects (aPR = 1.06, 95%CI [1.01–1.12]), as well as poor vaccine literacy (aPR = 1.07, 95%CI [1.01–1.14]). Interestingly, the belief in COVID-19 vaccine effectiveness reduced OCV hesitancy by 24% (aPR = 0.76, 95%CI [0.62–0.93]). COVID-19 vaccine hesitancy and its drivers exhibited a significant domino effect on OCV uptake. Addressing vaccine hesitancy through community-based health literacy and trust-building interventions would likely improve the introduction of novel non-COVID-19 vaccines in the post-COVID-19 era.
Open AccessCOVID-19 Vaccine Hesitancy and Associated Oral Cholera Vaccine Hesitancy in a Cholera-Endemic Country: A Community-Based Cross-Sectional Study in the Democratic Republic of Congo
COVID-19 vaccine hesitancy and its enablers shape community uptake of non-covid vaccines such as the oral cholera vaccine (OCV) in the post-COVID-19 era. This study assessed the impact of COVID-19 vaccine hesitancy and its drivers on OCV hesitancy in a cholera-endemic region of the Democratic Republic of Congo. We conducted a community-based survey in Bukavu. The survey included demographics, intention to take OCV and COVID-19 vaccines, reasons for COVID-19 hesitancy, and thoughts and feelings about COVID-19 vaccines. Poisson regression analyses were performed. Of the 1708 respondents, 84.66% and 77.57% were hesitant to OCV alone and to both OCV and COVID-19, respectively. Hesitancy to COVID-19 vaccines rose OCV hesitancy by 12% (crude prevalence ratio, [cPR] = 1.12, 95%CI [1.03–1.21]). Independent predictors of OCV hesitancy were living in a semi-urban area (adjusted prevalence ratio [aPR] = 1.10, 95%CI [1.03–1.12]), religious refusal of vaccines (aPR = 1.06, 95%CI [1.02–1.12]), concerns about vaccine safety (aPR = 1.05, 95%CI [1.01–1.11]) and adverse effects (aPR = 1.06, 95%CI [1.01–1.12]), as well as poor vaccine literacy (aPR = 1.07, 95%CI [1.01–1.14]). Interestingly, the belief in COVID-19 vaccine effectiveness reduced OCV hesitancy by 24% (aPR = 0.76, 95%CI [0.62–0.93]). COVID-19 vaccine hesitancy and its drivers exhibited a significant domino effect on OCV uptake. Addressing vaccine hesitancy through community-based health literacy and trust-building interventions would likely improve the introduction of novel non-COVID-19 vaccines in the post-COVID-19 era.
- Open Access
Socio-Demographic Factors Influencing Malaria Vaccine Acceptance for Under-Five Children in a Malaria-Endemic Region: A Community-Based Study in the Democratic Republic of Congo
Two novel vaccines against malaria are proposed as a complementary control tool to prevent and reduce Plasmodium falciparum related disease and death in under-five children from moderate to high malaria transmission regions. The Democratic Republic of Congo (DRC) has committed to eradicate malaria by 2030, and significant efforts have been deployed to strengthen control and elimination measures. We aimed to understand factors influencing the malaria vaccine acceptability among the general population in eastern DRC. We conducted a survey among adult Congolese in Bukavu in March 2022. The questionnaire was adapted from the Behavioral and Social Drivers of vaccine uptake (BeSD) framework and was administered online and physically. Multivariate logistic regressions were built, and estimates were represented as adjusted odds ratios (aOR) and corresponding 95% confidence intervals (95%CI). Out of 1612 adults (median age: 39 years, 46.15% female) surveyed, only 7.26% were aware of the malaria vaccine. However, 46.53% expressed willingness to vaccinate themselves, and 52.60% were open to vaccinating their under-five children. Adjusting for confounding factors, non-student/non-healthcare worker professions (aOR = 0.58, 95%CI [0.42–0.78]) and middle-income status (aOR = 1.87, 95%CI [1.25–2.80]) were significantly associated with self-vaccination acceptance. Age played a role in under-five child vaccination acceptability, with 25 to over 64 years showing increased acceptability compared to the 18–24 age group. Additionally, non-student/non-healthcare worker professions (aOR = 1.88, 95%CI [1.37–2.59]), medium education levels (aOR = 2.64, 95%CI [1.29–5.79]), and residing in semi-rural areas (aOR = 1.63, 95%CI [1.27–2.10]) were predictors of under-five child vaccination acceptance. The acceptability of the malaria vaccine for self and for under-five children was suboptimal for effective malaria control in this community in the DRC. Our study constitutes a call for the Expanded Program on Immunization to closely work with various stakeholders to strengthen risk communication for community engagement prior to and during the introduction of this novel and lifesaving tool, malaria vaccination.
Open AccessSocio-Demographic Factors Influencing Malaria Vaccine Acceptance for Under-Five Children in a Malaria-Endemic Region: A Community-Based Study in the Democratic Republic of Congo
Two novel vaccines against malaria are proposed as a complementary control tool to prevent and reduce Plasmodium falciparum related disease and death in under-five children from moderate to high malaria transmission regions. The Democratic Republic of Congo (DRC) has committed to eradicate malaria by 2030, and significant efforts have been deployed to strengthen control and elimination measures. We aimed to understand factors influencing the malaria vaccine acceptability among the general population in eastern DRC. We conducted a survey among adult Congolese in Bukavu in March 2022. The questionnaire was adapted from the Behavioral and Social Drivers of vaccine uptake (BeSD) framework and was administered online and physically. Multivariate logistic regressions were built, and estimates were represented as adjusted odds ratios (aOR) and corresponding 95% confidence intervals (95%CI). Out of 1612 adults (median age: 39 years, 46.15% female) surveyed, only 7.26% were aware of the malaria vaccine. However, 46.53% expressed willingness to vaccinate themselves, and 52.60% were open to vaccinating their under-five children. Adjusting for confounding factors, non-student/non-healthcare worker professions (aOR = 0.58, 95%CI [0.42–0.78]) and middle-income status (aOR = 1.87, 95%CI [1.25–2.80]) were significantly associated with self-vaccination acceptance. Age played a role in under-five child vaccination acceptability, with 25 to over 64 years showing increased acceptability compared to the 18–24 age group. Additionally, non-student/non-healthcare worker professions (aOR = 1.88, 95%CI [1.37–2.59]), medium education levels (aOR = 2.64, 95%CI [1.29–5.79]), and residing in semi-rural areas (aOR = 1.63, 95%CI [1.27–2.10]) were predictors of under-five child vaccination acceptance. The acceptability of the malaria vaccine for self and for under-five children was suboptimal for effective malaria control in this community in the DRC. Our study constitutes a call for the Expanded Program on Immunization to closely work with various stakeholders to strengthen risk communication for community engagement prior to and during the introduction of this novel and lifesaving tool, malaria vaccination.
- Open Access
- 6 March 2024
- Published by MDPI AG in Preprints.org
COVID-19 Vaccine Hesitancy and Associated Oral Cholera Vaccine Hesitancy in a Cholera Endemic Country, the Democratic Republic of Congo
COVID-19 vaccine hesitancy and its enablers would shape community uptake of non-covid vaccines such as oral cholera vaccine (OCV) in the post-COVID-19 era. This study assessed the impact of COVID-19 vaccine hesitancy and its drivers on OCV hesitancy in a cholera endemic region of the Democratic Republic of Congo. We conducted a community-based survey in Bukavu. The survey included characteristics, intention to take OCV and COVID-19, reasons for COVID-19 hesitancy, and thinking and feeling about COVID-19 vaccines. Poisson regression analyses were performed. Of the 1708 respondents, 84.66% and 77.57% were hesitant to OCV alone and to both OCV and COVID-19, respectively. Hesitancy to COVID-19 vaccines rose OCV hesitancy by 12% (crude Prevalence Ratio, [cPR]=1.12, 95%CI[1.03-1.21]). Independent predictors of OCV hesitancy were living in semi-urban area (adjusted Prevalence Ratio [aPR]=1.10, 95%CI[1.03-1.12]), religious refusal of vaccines (aPR=1.06, 95%CI[1.02-1.12]), concerns about vaccine safety (aPR=1.05, 95%CI[1.01-1.11]) and adverse effects (aPR=1.06, 95%CI[1.01-1.12]), as well as poor knowledge (aPR=1.07, 95%CI[1.01-1.14]). Conversely, the belief about COVID-19 vaccine effectiveness reduced OCV hesitancy (aPR=0.76, 95%CI[0.62-0.93]). COVID-19 vaccine hesitancy and its drivers exhibiting a significant domino effect on OCV uptake. Addressing vaccine hesitancy through community-based health literacy interventions would likely improve the introduction of novel non-COVID-19 vaccines in post-COVID-19 era.
- 6 March 2024
- Published by MDPI AG in Preprints.org
Open AccessCOVID-19 Vaccine Hesitancy and Associated Oral Cholera Vaccine Hesitancy in a Cholera Endemic Country, the Democratic Republic of Congo
COVID-19 vaccine hesitancy and its enablers would shape community uptake of non-covid vaccines such as oral cholera vaccine (OCV) in the post-COVID-19 era. This study assessed the impact of COVID-19 vaccine hesitancy and its drivers on OCV hesitancy in a cholera endemic region of the Democratic Republic of Congo. We conducted a community-based survey in Bukavu. The survey included characteristics, intention to take OCV and COVID-19, reasons for COVID-19 hesitancy, and thinking and feeling about COVID-19 vaccines. Poisson regression analyses were performed. Of the 1708 respondents, 84.66% and 77.57% were hesitant to OCV alone and to both OCV and COVID-19, respectively. Hesitancy to COVID-19 vaccines rose OCV hesitancy by 12% (crude Prevalence Ratio, [cPR]=1.12, 95%CI[1.03-1.21]). Independent predictors of OCV hesitancy were living in semi-urban area (adjusted Prevalence Ratio [aPR]=1.10, 95%CI[1.03-1.12]), religious refusal of vaccines (aPR=1.06, 95%CI[1.02-1.12]), concerns about vaccine safety (aPR=1.05, 95%CI[1.01-1.11]) and adverse effects (aPR=1.06, 95%CI[1.01-1.12]), as well as poor knowledge (aPR=1.07, 95%CI[1.01-1.14]). Conversely, the belief about COVID-19 vaccine effectiveness reduced OCV hesitancy (aPR=0.76, 95%CI[0.62-0.93]). COVID-19 vaccine hesitancy and its drivers exhibiting a significant domino effect on OCV uptake. Addressing vaccine hesitancy through community-based health literacy interventions would likely improve the introduction of novel non-COVID-19 vaccines in post-COVID-19 era.
- Open Access
- 1 February 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (3) , ofae058
Cholera Deaths During Outbreaks in Uvira, Eastern Democratic Republic of the Congo, 10–35 Months After Mass Vaccination
Our understanding of the burden and drivers of cholera mortality is hampered by limited surveillance and confirmation capacity. Leveraging enhanced clinical and laboratory surveillance in the cholera-endemic community of Uvira, eastern Democratic Republic of Congo, we describe cholera deaths across 3 epidemics between September 2021 and September 2023 following mass vaccination.
- 1 February 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (3) , ofae058
Open AccessCholera Deaths During Outbreaks in Uvira, Eastern Democratic Republic of the Congo, 10–35 Months After Mass Vaccination
Our understanding of the burden and drivers of cholera mortality is hampered by limited surveillance and confirmation capacity. Leveraging enhanced clinical and laboratory surveillance in the cholera-endemic community of Uvira, eastern Democratic Republic of Congo, we describe cholera deaths across 3 epidemics between September 2021 and September 2023 following mass vaccination.